There were 2,235 press releases posted in the last 24 hours and 359,216 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image